PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.

PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.
Trends Immunol. 2019 Apr 09;:
Authors: Wartewig T, Ruland J
Abstract
The inhibitory receptor PD-1 is critical to balancing antigen-induced T cell activation; its inhibition is currently being explored to enhance antitumor T cell immunity with certain successful outcomes. However, PD-1 has also emerged as a central tumor suppressor in T cell lymphomas, where the tumor cell originates from a T cell itself. These aggressive cancers are frequently characterized by oncogenic mutations in T cell receptor (TCR) signaling pathways. PD-1 activity within malignant T cells can negatively regulate the PI3K/AKT and PKCθ/NF-κB tumor survival pathways and PD-1 is frequently inactivated in this human malignancy. This review summarizes current insights into oncogenic T cell signaling, discusses tumor-suppressive functions and mechanisms of PD-1 in T cell lymphomagenesis, and addresses potential unwanted effects caused by PD-1 checkpoint inhibition.
PMID: 30979616 [PubMed - as supplied by publisher]

Source: Trends in Immunology - April 8, 2019 Category: Allergy & Immunology Authors: Wartewig T, Ruland J Tags: Trends Immunol Source Type: research